Article (Scientific journals)
(18)F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab.
Fosse, Pacome; KAISER, Marie-Joëlle; Namur, Gauthier et al.
2018In European Journal of Hybrid Imaging, 2 (1), p. 6
Peer Reviewed verified by ORBi
 

Files


Full Text
18F- FDG PET-CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab.pdf
Publisher postprint (634.67 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
18F- FDG; PET/CT; Rheumatoid arthritis; Rituximab
Abstract :
[en] Background: (18)F-FDG PET/CT has been proposed in the evaluation of the disease activity in rheumatoid arthritis (RA). The goals of this study were to evaluate the reproducibility of the technique, to compare metabolic parameters to clinical, biological and ultrasonographic parameters before and after treatment and to evaluate whether the early metabolic response was related to the outcome. (18)F- FDG PET/CT of the hands, wrists and knees was obtained in 15 patients with anti-TNFalpha refractory RA, at baseline and 16 weeks after treatment with rituximab. The number of PET-positive joints (PET+ joints), the cumulative standard uptake value (cSUV) and the composite index (CI) were defined. The composite clinical index DAS28, CRP serum levels and the number of joints positive at ultrasonography (US+ joints) and the cumulative synovial thickness (CST) were also assessed at baseline and week 24. Results: High interobserver agreement was observed, both at baseline and after treatment. The number of PET+ joints was not correlated with the number of joints tender or swollen. The 3 metabolic parameters were strongly correlated with US, CRP and DAS28 at baseline and with US and CRP (CSUV, CI) at week 16, but no longer with the DAS28 index. The metabolic response based on the change in the visual PET/CT joint analysis predicted the outcome with a high negative predictive value of 91%, with a 91% specificity, and an 86% accuracy. Conclusions: These preliminary data suggest that (18)F- FDG PET/CT is a reproducible and accurate tool for evaluating disease activity in refractory rheumatoid arthritis and its non-response to rituximab. The correlation obtained with US joint assessment gives relevance to objective diseased joints through imaging techniques.
Disciplines :
Rheumatology
Radiology, nuclear medicine & imaging
Author, co-author :
Fosse, Pacome;  Centre Hospitalier Universitaire d'Angers - CHU ANGERS > Service de Médecine nucléaire
KAISER, Marie-Joëlle ;  Centre Hospitalier Universitaire de Liège - CHU > Service de rhumatologie
Namur, Gauthier;  Clinique Saint-Joseph (Liège) > Service de Médecine nucléaire
DE SENY, Dominique ;  Centre Hospitalier Universitaire de Liège - CHU > Service de rhumatologie
Malaise, Michel ;  Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Hustinx, Roland  ;  Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire
Language :
English
Title :
(18)F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab.
Publication date :
2018
Journal title :
European Journal of Hybrid Imaging
eISSN :
2510-3636
Publisher :
Springer, London, United Kingdom
Volume :
2
Issue :
1
Pages :
6
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 13 June 2018

Statistics


Number of views
66 (4 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
22
Scopus citations®
without self-citations
22
OpenCitations
 
14

Bibliography


Similar publications



Contact ORBi